Trial Profile
Use of Combined Measurements of Serum Infliximab and Anti-Infliximab Antibodies in the Treatment of Patients With Crohns Disease Failing Infliximab Therapy.
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- 24 Nov 2011 Additional lead trial centres identified as reported by ClinicalTrials.gov.
- 24 Nov 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 12 Nov 2010 Additional lead trial investigators identified as reported by ClinicalTrials.gov.